《2019年ERA注册机构年度报告：总结与年龄比较》
The ERA Registry Annual Report 2019: summary and age comparisons.
作者信息
Boenink Rianne, Astley Megan E, Huijben Jilske A, Stel Vianda S, Kerschbaum Julia, Ots-Rosenberg Mai, Åsberg Anders A, Lopot Frantisek, Golan Eliezer, Castro de la Nuez Pablo, Rodríguez Camblor Marta, Trujillo-Alemán Sara, Ruiz San Millan Juan Carlos, Ucio Mingo Pablo, Díaz Juan Manuel, Bouzas-Caamaño M Encarnación, Artamendi Marta, Aparicio Madre Manuel I, Santiuste de Pablos Carmen, Slon Roblero María Fernanda, Zurriaga Oscar, Stendahl Maria E, Bell Samira, Idrizi Alma, Ioannou Kyriakos, Debska-Slizien Alicja, Galvão Ana A, De Meester Johan M, Resić Halima, Hommel Kristine, Radunovic Danilo, Pálsson Runolfur, Lassalle Mathilde, Finne Patrik, De Los Ángeles-Garcia Bazaga María, Gjorgjievski Nikola, Seyahi Nurhan, Bonthuis Marjolein, Ortiz Alberto, Jager Kitty J, Kramer Anneke
机构信息
ERA Registry, Department of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health research institute, Amsterdam, The Netherlands.
Austrian Dialysis and Transplant Registry, Department of Internal Medicine IV-Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.
出版信息
Clin Kidney J. 2021 Dec 15;15(3):452-472. doi: 10.1093/ckj/sfab273. eCollection 2022 Mar.
BACKGROUND
Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons.
METHODS
Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated.
RESULTS
In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010-14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities.
背景
欧洲肾脏协会（ERA）注册机构通过欧洲及地中海沿岸国家的国家和地区肾脏注册机构收集了终末期肾病的肾脏替代治疗（RRT）数据。本文总结了2019年ERA注册机构年度报告，包括来自34个国家的数据及额外的年龄比较。
方法
2019年的个体患者数据由35个注册机构提供，汇总数据由17个注册机构提供。利用这些数据，计算了RRT的发病率和患病率、肾脏移植活动及生存概率。
结果
2019年，ERA注册机构覆盖的总人口为6.808亿。总体而言，RRT的发病率为每百万人口132例（p.m.p.）。在这些患者中，62%为男性，54%年龄≥65岁，21%以糖尿病作为原发性肾脏疾病（PRD），84%接受血液透析（HD），11%接受腹膜透析（PD），5%以抢先肾移植作为初始治疗方式。2019年12月31日RRT的总体患病率为每百万人口893例，其中58%的患者接受HD，5%接受PD，37%为肾移植受者。总体肾脏移植率为每百万人口35例，29%的肾移植来自活体供体。在2010 - 14年期间，开始透析的患者未经调整的5年生存概率为42.3%， deceased donor移植受者为86.6%，活体供体移植受者为94.4%。在比较不同年龄组时，PRD的分布、治疗方式和肾脏供体类型以及生存概率存在显著差异。
Zotero 插件